Small nucleic acid medications have shown great promise in individualised medicine and therapy. At Protheragen MedAI, we care about cutting-edge therapies and offer customized contract development and manufacturing organization (CDMO) services for small nucleic acid drugs. With strict synthesis and quality control, we aim to keep small nucleic acid medications effective and safe.

Development Methods for Small Nucleic Acid Drugs

Traditionally, a range of methods for small nucleic acid drug development have been utilized, including:

• Solid-phase synthesis
• Liquid-phase synthesis
• Enzymatic synthesis
• Chemical degradation methods
• Automated synthesis

Liquid-Phase Synthesis

At Protheragen MedAI, we use liquid-phase synthesis to manufacture stable and safe small nucleic acid drugs, offering high precision and scalability. This technique involves the chemical synthesis of nucleic acids in a liquid solution, allowing controlled and efficient production.

• Sequential Addition

Nucleotide monomers are added one by one to the expanding chain of liquids by an automated system.

• Controlled Conditions

The reaction conditions of the process are tightly controlled, including temperature, pH and reagent concentration.

• Purification

The oligonucleotides are purified using advanced techniques such as HPLC.

Advantages of Liquid-Phase Synthesis

Protheragen MedAI's formulation development and GMP-registered scale-up production services will help you successfully bring your product from idea to market. We start with extensive pre-formulation research to determine API properties and excipient compatibility. We use this information to build stable, effective formulations for you, until such formulations can be seamlessly moved into scale-up production. Protheragen MedAI meticulously adheres to Good Manufacturing Practice (GMP) standards, optimizing the manufacturing process to maintain consistency, quality, and regulatory compliance throughout.

• Scalability   

Liquid-phase synthesis can be easily scaled from laboratory to production scale with different numbers of nucleic acids as required.  

• Flexibility

It allows us to synthesize multiple sequences of nucleic acids very precisely, and is therefore appropriate for complex and multi-dimensional oligonucleotide structures.

• Enhanced Purity

The liquid-phase environment supports better separation of products and impurities, leading to high-purity final products.

• Automated Processing

Automated systems can be employed to streamline the synthesis process, improving reproducibility and efficiency.

Why Choose Us?

• Expertise

The vast production experience of our team of scientists and researchers guarantees a successful delivery of small nucleic acid drug manufacturing experiences.

• Quality Assurance

Our primary priority is quality. At every step of the manufacturing process, we have rigorous quality control processes to ensure that the product meets the highest standards of safety and purity.

• Transparent Reporting

To guarantee openness and satisfaction at every turn, each project is backed by thorough quality reports.

• On-Time Delivery

We promise to fulfill deadlines by delivering things on time.

Our liquid-phase synthesis approach ensures that small nucleic acid drugs are produced with exceptional precision and quality, supporting the development of cutting-edge therapies. With our expertise and advanced technology, Protheragen MedAI is well-equipped to meet your specific needs in nucleic acid drug development, offering reliable and scalable solutions to drive your innovative projects forward. For more details on our small nucleic acid drug CDMO services and how we can assist you, please contact us.